Please login to the form below

Not currently logged in
Email:
Password:

Lundbeck promotes Andreas Eggert and Klaus Abel to senior commercial roles

Will oversee launch of new medicines and Otsuka partnership respectively

Danish pharma firm Lundbeck has promoted Andreas Eggert to senior VP for global product strategy and Klaus Abel to VP with responsibility for commercialisation of medicines from Lundbeck's partnership with Otsuka Pharmaceuticals.

Eggert, who joined Lundbeck in 2010 as VP for global product strategy, will have overall responsibility for the launches of several new medicines from Lundbeck during the next 18 months, including vortioxetine for major depression and Selincro (nalmefene) for alcohol dependence.

Prior to joining Lundbeck, Eggert spent several years at Wyeth (now part of Pfizer) where his roles included serving as director global strategic marketing and VP and global business manager.

Andreas Eggert - LundbeckKlaus Abel - Lundbeck
Andreas Eggert and Klaus Abel

Abel's responsibilities will cover the collaborative development and commercialisation of medicines Lundbeck is working on with Otsuka as part of a multi-billion dollar deal, including a once-monthly aripiprazole formulation for the treatment of schizophrenia and brexpiprazole (OPC-34712) for the treatment of schizophrenia and major depression.

Abel, who has been with Lundbeck since 2000, and was most recently executive director with commercial responsibility for several products, will report to Eggert who will in turn report directly to president and CEO Ulf Wiinberg.

23rd August 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....